Established Medical Therapy for Benign Prostatic Hyperplasia
Authors:
- Brian T. HelfandBHBrian T. Helfand
- Kevin T. McVaryKMKevin T. McVary
- 1 November 2009
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 36 (4) , 443-459
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Benign Prostatic Hyperplasia: What About a Campaign for Prevention?Urologia Internationalis, 2004
- Messenger RNA levels and enzyme activities of 5 alpha‐reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissueThe Prostate, 2003
- DutasterideDrugs & Aging, 2003
- MODULATION OF BLADDER α1-ADRENERGIC RECEPTOR SUBTYPE EXPRESSION BY BLADDER OUTLET OBSTRUCTIONJournal of Urology, 2002
- TamsulosinDrugs & Aging, 2002
- Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2000
- Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasiaThe Prostate, 1996
- Tamsulosin, a selective α 1c ‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasiaThe Prostate, 1993
- Preliminary NoteBritish Journal of Urology, 1982